Peptide Knowledge Base · GH-axis
Tesamorelin: what it is, what the evidence says, and its real status
A growth-hormone-axis peptide with FDA-approved origins.
Short version: the GH-axis peptide with the strongest pedigree, FDA-approved origins (Egrifta). Available by request and supervised, though compounded forms aren't the approved product.
Can you actually get it?
Plain-English verdict: Waitlist.
Regulatory status: FDA-approved (branded) · by request · SKU request.
By request, clinician-evaluated. An FDA-approved branded product exists (Egrifta); compounded forms are not the approved product and are not FDA-approved.
How does Tesamorelin work?
A stabilized GHRH analog that stimulates endogenous growth-hormone release; FDA-approved as Egrifta for a specific indication.
What it does — and what it does not do
What it does: Used for GH-axis and metabolic support under clinician supervision.
What it does not do: Compounded versions are not FDA-approved, and it is not a general weight-loss drug.
How honest is the evidence?
Evidence grade A — randomized human trials behind the approved product (Egrifta). Read our grading methodology for what each grade means.
What we still don't know: Long-term use beyond studied indications is less characterized.
WADA status: Banned (S2).
How it is taken
Clinician-set; subcutaneous.
Who should not take it
Banned in tested sport (WADA S2); contraindicated in active malignancy and pregnancy. Clinician-gated.
Sources
Falutz et al., tesamorelin trials, NEJM 2007 · FDA Egrifta labeling
Compounded medications are not FDA-approved. We keep two signals separate and never collapse them: whether you can get something, and what the rule currently says. See the live FDA Peptide Tracker or the knowledge base.
Last reviewed 2026-08-11 · Peptós.LIFE · Not medical advice.